{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:32:20Z","timestamp":1785148340794,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP17H04009"],"award-info":[{"award-number":["JP17H04009"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K19401"],"award-info":[{"award-number":["JP18K19401"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.heliyon.2020.e04301","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T16:16:11Z","timestamp":1593274571000},"page":"e04301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vaccine effect of recombinant single-chain hemagglutinin protein as an antigen"],"prefix":"10.1016","volume":"6","author":[{"given":"Atsushi","family":"Kawai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-8630","authenticated-orcid":false,"given":"Yasuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7265-9221","authenticated-orcid":false,"given":"Yasuo","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.heliyon.2020.e04301_bib1","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The biology of influenza viruses","volume":"26","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2020.e04301_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2020.e04301_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.chom.2018.06.016","article-title":"Overcoming barriers in the path to a universal influenza virus vaccine","volume":"24","author":"Coughlan","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.heliyon.2020.e04301_bib4","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/cid\/ciw635","article-title":"2014-2015 influenza vaccine effectiveness in the United States by vaccine type","volume":"63","author":"Zimmerman","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2020.e04301_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2020.e04301_bib6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.tim.2017.06.008","article-title":"Epidemiology, evolution, and pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in China","volume":"25","author":"Su","year":"2017","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.heliyon.2020.e04301_bib7","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1128\/JVI.00187-08","article-title":"Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus","volume":"82","author":"Wei","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.heliyon.2020.e04301_bib8","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.01035-10","article-title":"Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets","volume":"84","author":"Bosch","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.heliyon.2020.e04301_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010645","article-title":"A\u00a0single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1","volume":"5","author":"Cornelissen","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.heliyon.2020.e04301_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012466","article-title":"Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin","volume":"5","author":"Weldon","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.heliyon.2020.e04301_bib11","doi-asserted-by":"crossref","first-page":"7436","DOI":"10.1074\/jbc.M114.620534","article-title":"Immunosilencing a highly immunogenic protein trimerization domain","volume":"290","author":"Sliepen","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.heliyon.2020.e04301_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2017.06.005","article-title":"Old and new adjuvants","volume":"47","author":"McKee","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2020.e04301_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/14760584.2014.863715","article-title":"Recent progress concerning CpG DNA and its use as a vaccine adjuvant","volume":"13","author":"Shirota","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.heliyon.2020.e04301_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12390","article-title":"Immunogenicity of therapeutic recombinant immunotoxins","volume":"270","author":"Mazor","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.heliyon.2020.e04301_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.coi.2010.04.002","article-title":"Designing CD8+ T cell vaccines: it's not rocket science (yet)","volume":"22","author":"Yewdell","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2020.e04301_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.15585\/mmwr.mm6715a5","article-title":"Recommendations of the advisory committee on immunization practices for use of a hepatitis B vaccine with a novel adjuvant","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.heliyon.2020.e04301_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/IJN.S114477","article-title":"CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies","volume":"12","author":"Hanagata","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.heliyon.2020.e04301_bib18","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1016\/S0021-9258(18)47090-1","article-title":"Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding","volume":"269","author":"Brown","year":"1994","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.heliyon.2020.e04301_bib19","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.vaccine.2016.06.064","article-title":"Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: a systematic review and meta-analysis of randomised controlled trials","volume":"34","author":"Moa","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2020.e04301_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/vim.2017.0022","article-title":"Intranasal administration of whole inactivated influenza virus vaccine as a promising influenza vaccine candidate","volume":"30","author":"Ainai","year":"2017","journal-title":"Viral Immunol."},{"key":"10.1016\/j.heliyon.2020.e04301_bib21","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1128\/JVI.00641-13","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.heliyon.2020.e04301_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/JVI.02608-13","article-title":"Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain","volume":"88","author":"Eggink","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.heliyon.2020.e04301_bib23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A\u00a0stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2020.e04301_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coviro.2016.02.002","article-title":"Novel universal influenza virus vaccine approaches","volume":"17","author":"Krammer","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.heliyon.2020.e04301_bib25","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1128\/JVI.76.9.4634-4642.2002","article-title":"Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin","volume":"76","author":"Yang","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.heliyon.2020.e04301_bib26","doi-asserted-by":"crossref","first-page":"25506","DOI":"10.1074\/jbc.M110.101170","article-title":"Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides","volume":"285","author":"Chen","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.heliyon.2020.e04301_bib27","doi-asserted-by":"crossref","first-page":"12111","DOI":"10.1073\/pnas.1204533109","article-title":"HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120","volume":"109","author":"Kovacs","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2020.e04301_bib28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2020.e04301_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071072","article-title":"A\u00a0protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles","volume":"8","author":"Rigter","year":"2013","journal-title":"PloS One"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020311452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020311452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T04:48:36Z","timestamp":1764218916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844020311452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2405844020311452"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04301","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine effect of recombinant single-chain hemagglutinin protein as an antigen","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e04301"}}